Fox Run Management, L.L.C. Intra Cellular Therapies, Inc. Transaction History

Fox Run Management, L.L.C.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$64.76 - $79.84 $1.2 Million - $1.48 Million	18,575 New	18,575 $1.27 Million
Q4 2023 Feb 13, 2024	BUY	$46.37 - $73.65 $152,510 - $242,234	3,289 New	3,289 $235,000
Q3 2022 Nov 07, 2022	SELL	$42.7 - $59.99 $15,329 - $21,536	-359 Reduced 4.12%	8,357 $389,000
Q2 2022 Aug 12, 2022	BUY	$43.0 - $65.64 $374,788 - $572,118	8,716 New	8,716 $498,000
Q4 2020 Feb 08, 2021	SELL	$23.34 - $32.22 $253,985 - $350,618	-10,882 Closed	0 $0
Q3 2020 Oct 29, 2020	BUY	$17.61 - $31.86 $191,632 - $346,700	10,882 New	10,882 $279,000
Q4 2018 Jan 15, 2019	SELL	$10.36 - $20.96 $104,729 - $211,884	-10,109 Closed	0 $0
Q3 2018 Oct 05, 2018	SELL	$17.77 - $22.9 $356,341 - $459,213	-20,053 Reduced 66.48%	10,109 $219,000
Q2 2018 Jul 17, 2018	BUY	$17.33 - $23.4 $522,707 - $705,790	30,162 New	30,162 $533,000
Q1 2018 Apr 17, 2018	SELL	$15.16 - $25.49 $403,635 - $678,671	-26,625 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$14.27 - $16.79 $27,469 - $32,320	1,925 Added 7.79%	26,625 $386,000
Q3 2017 Oct 23, 2017	BUY	$10.77 - $22.1 $266,019 - $545,870	24,700	24,700 $390,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.